• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PYRIDOSTIGMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • PYRIDOSTIGMINE chembl:CHEMBL1115 Approved

    Alternate Names:

    REGONOL
    MESTINON
    PYRIDOSTIGMINE
    MESTINON®
    REGONOL®
    BROMURO DE PIRIDOSTIGMINA
    PYRIDOSTIGMIN BROMID
    BROMURE DE PYRIDOSTIGMINE
    PYRIDOSTIGMINI BROMIDUM
    pubchem.compound:4991
    chemidplus:155-97-5
    rxcui:9000
    chembl:CHEMBL1115
    drugbank:00545

    Drug Info:

    Drug Class antimyasthenics
    Year of Approval 1955
    Drug Class small molecule
    Drug Indications Antimyasthenics
    FDA Approval 1955
    (1 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Ricordel et al., 2000, [Chemical weapons: antidotes. View about the real means, perspectives]., Ann Pharm Fr
    Servatius et al., 2000, Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats., Physiol. Behav.
    Drake-Baumann et al., 1999, Effects of exposure to low-dose pyridostigmine on neuromuscular junctions in vitro., Muscle Nerve
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Prasad et al., 2000, Interactions of bovine brain tubulin with pyridostigmine bromide and N,N'-diethyl-m-toluamide., Neurochem. Res.
    Sinton et al., 2000, Stressful manipulations that elevate corticosterone reduce blood-brain barrier permeability to pyridostigmine in the Rat., Toxicol. Appl. Pharmacol.
  • PYRIDOSTIGMINE   ACHE

    Interaction Score: 2.26

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10669805 10869589 10366222 11752352 10685600 10814558


    Sources:
    TdgClinicalTrial TEND TTD

  • PYRIDOSTIGMINE   CBX1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PYRIDOSTIGMINE   CYP2C9

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PYRIDOSTIGMINE   CYP1A2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PYRIDOSTIGMINE   CYP2D6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PYRIDOSTIGMINE   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: PYRIDOSTIGMINE

    • Version: 01-August-2011

    Alternate Names:
    PYRIDOSTIGMINE Primary Drug Name

    Drug Info:
    Year of Approval 1955
    Drug Class antimyasthenics

    Publications:

  • TdgClinicalTrial: PYRIDOSTIGMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    FDA Approval 1955
    Drug Indications Antimyasthenics
    Drug Class small molecule

    Publications:

  • DTC: PYRIDOSTIGMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1115 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • TTD: Pyridostigmine

    • Version: 2020.06.01

    Alternate Names:
    D0O2WB TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1115

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21